Abstract
Following power law, Farr’s law and IDEA model, we analyze the data of COVID-19 pandemic for India up to 2 May, 2020 and for Germany, France, Italy, the USA, Singapore, China and Denmark up to 26 April, 2020. The cumulative total number of infected persons as a function of elapsed time has been fitted with power law to find the scaling exponent (γ). The reduction in γ in different countries signals the reduction in the growth of infection, possibly, due to long-term Government intervention. The extent of infection and reproduction rate R0 of the same are also examined using Farr’s law and IDEA model. The new cases per day with time assume Gaussian bell shaped curve, obeying the rule that faster rise follows faster decay. In India and Singapore, the peak of the bell shaped curve is still elusive. It is found that, till date, countries such as Denmark and India implementing sooner lockdown have underwent lower number of new cases of infection. Daily variation shows, R0 of all the countries is reducing, ushering in fresh hopes to combat COVID-19. Finally, we try to make a prediction as to the date on which the different countries will come down to daily cases of infection as low as one hundred (100).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding is involved.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data referred in our manuscript are available in the internet.
